SYMBICORT Drug Patent Profile

When do Symbicort patents expire, and what generic alternatives are available?

Symbicort is a drug marketed by Astrazeneca and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SYMBICORT is budesonide; formoterol fumarate. There are twenty-two drug master file entries for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort

Annual sales in 2022 were $3.6bn, indicating a strong incentive for generic entry (peak sales were $5.7bn in 2019).

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBICORT

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Clinical Trials:	146
Drug Prices:	Drug price information for SYMBICORT
Drug Sales Revenues:	Drug sales revenues for SYMBICORT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBICORT
What excipients (inactive ingredients) are in SYMBICORT?	SYMBICORT excipients list
DailyMed Link:	SYMBICORT at DailyMed

See drug prices for SYMBICORT

See drug sales revenues for SYMBICORT

Recent Clinical Trials for SYMBICORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AstraZeneca	PHASE4
Morten Hostrup, PhD	N/A
University of Alberta	Phase 1

See all SYMBICORT clinical trials

Pharmacology for SYMBICORT

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for SYMBICORT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBICORT	Metered Inhalation	budesonide; formoterol fumarate dihydrate	80 mcg/4.5 mcg per inhalation and 160 mcg/4.5 mcg per inhalation	021929	1	2018-06-26

US Patents and Regulatory Information for SYMBICORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	AB	RX	Yes	Yes
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	9,415,009
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-002	Apr 27, 2026		RX	Yes	Yes	10,716,753		Y

Expired US Patents for SYMBICORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-002	Jul 21, 2006	5,674,860
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	5,349,945
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	5,972,919

EU/EMA Drug Approvals for SYMBICORT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva Pharma B.V.	Budesonide/Formoterol Teva Pharma B.V.	budesonide, formoterol fumarate dihydrate	EMEA/H/C/004882Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1)	Authorised	no	no	no	2020-04-03
Teva Pharma B.V.	Budesonide/Formoterol Teva Pharma B.V.	budesonide, formoterol fumarate dihydrate	EMEA/H/C/003953Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.	Withdrawn	no	no	no	2014-11-19

International Patents for SYMBICORT

See the table below for patents covering SYMBICORT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	423552
Austria	463241
Australia	2003206289

Supplementary Protection Certificates for SYMBICORT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	CA 2002 00019	Denmark
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
0613371	SPC016/2002	Ireland		SPC016/2002: 20041105, EXPIRES: 20150824

SYMBICORT market dynamics and financial trajectory: sales drivers, pricing pressure, payer leverage, and patent-driven generic entry risk

Last updated: July 19, 2026

Executive summary

• SYMBICORT (budesonide/formoterol fumarate dihydrate) remains a top-tier US inhaled corticosteroid/long-acting beta agonist (ICS/LABA) franchise with sustained demand driven by chronic obstructive pulmonary disease (COPD) and asthma maintenance use.
• The financial trajectory is shaped more by class competition, channel contracting, and formulary access than by near-term exclusivity cliffs, with generic and biosimilar-style replacement dynamics occurring through lower-cost ICS/LABA options and therapeutic interchange rather than a single abrupt “all-at-once” loss of brand coverage.
• Patent estate durability, combination formulation/method IP, and line-extension filings are central to the pace of erosion, while US payer utilization management (tiering, step edits, and preferred-agent lists) determines the realized gross-to-net path.
• The most material market risk for SYMBICORT is ICS/LABA competitive switching (including cheaper generics and alternative brands within ICS/LABA and adjacent triple-therapy pathways), which affects both volume and net price.

---

SYMBICORT market size, revenue drivers, and growth outlook

Quick answer: SYMBICORT demand is driven by durable control needs in asthma and COPD, but growth is constrained by steady channel contracting, competitive switching within ICS/LABA, and patient movement to other inhaler classes.

What does SYMBICORT sell (and why it holds share)?

SYMBICORT is marketed as:

• Asthma maintenance in patients who require ongoing controller therapy.
• COPD maintenance in patients who require both an inhaled corticosteroid and a long-acting bronchodilator.

Revenue drivers typically include:

• Prescription volume supported by chronic therapy adherence and guideline-consistent controller use.
• Formulary placement in commercial plans that cover ICS/LABA controllers.
• Device reliability and patient switching friction (patients often remain on an inhaler if tolerability and technique are stable).

Which subsegments matter most?

High-intent market analysis for SYMBICORT usually separates:

• Asthma (persistent controller use, step therapy pressure, and switching to alternative ICS/LABA combinations)
• COPD (maintenance use, substitution to other ICS/LABA or escalation to triple therapy)

How pricing and reimbursement dynamics typically flow to SYMBICORT net sales

Brand ICS/LABA net sales are dominated by:

• Rebates and discounts under managed care contracting.
• Medicaid and state coverage dynamics that differ materially from commercial.
• Wholesale channel inventory cycles that can create short-term volatility.

Bloomberg-style financial modeling inputs that track SYMBICORT revenue realization usually include:

• Net price trend vs class basket
• Formulary tier movement (preferred vs non-preferred)
• Mix shift by dose strength and device
• Estimated share change vs PBM-preferred ICS/LABA competitors

(No financial figures are provided here because a complete, accurate revenue trajectory requires primary sales and segment disclosure data by year, which is not available in the prompt.)

---

What market dynamics shape SYMBICORT sales in 2024–2026?

Quick answer: Class-wide competition, payer contracting, and COPD treatment migration toward triple therapy are the primary forces.

PBM contracting and formulary tier pressure

Managed care organizations increasingly steer patients toward:

• Preferred ICS/LABA products (often with lower acquisition costs)
• Plan-favored devices with lower copays
• Step therapy that delays or restricts access for non-preferred options

For SYMBICORT, the key market dynamic is whether it remains:

• Preferred at the point of prescribing, and
• Covered without restrictive step edits for typical maintenance cohorts.

COPD guideline migration to triple therapy

For many COPD patients, care pathways increasingly favor LABA/LAMA triple regimens or ICS/LABA/LAMA escalation depending on exacerbation history and biomarkers. That shifts:

• Some ICS/LABA volume to other combinations
• Prescriber willingness to use SYMBICORT as a long-term endpoint vs bridge to escalation

Competitive switching inside ICS/LABA

SYMBICORT faces substitution risk from:

• Other ICS/LABA brands
• Generic or lower-cost ICS/LABA options
• Combination inhalers with different co-pay dynamics

Device and adherence effects

Inhaler selection impacts adherence:

• If patients perceive easier actuation or better taste, they may resist switching.
• If payers impose restrictions, utilization can shift even when clinical switching friction exists.

---

When does SYMBICORT exclusivity end, and how does that affect generic entry risk?

Quick answer: The generic erosion pattern for older blockbuster inhalers like SYMBICORT is typically gradual, driven by competitive and payer switching rather than a single discontinuity.

How exclusivity generally influences erosion pace for inhaled combos

For inhaler brands, generic and market substitution usually depend on:

• Patent expiry timing for formulations, process, and device-related claims
• Specific strengths and inhaler device platforms that may remain protected longer
• Litigation outcomes affecting launch timing
• Label and guideline positioning that affects whether prescribers continue brand use

What “generic entry risk” means in ICS/LABA

A meaningful risk exists when:

• A lower-cost alternative becomes PBM-preferred, and
• The competitive product is clinically interchangeable for covered patients, and
• Any residual brand protection does not block routine dispensing.

---

Which patents protect SYMBICORT, and what formulation or method claims matter most?

Quick answer: The relevant IP for SYMBICORT typically clusters around combination formulations, process/manufacturing, and sometimes device or particle properties tied to deposition and delivery performance.

Patent estate categories to track for erosion risk

For SYMBICORT-style combination inhalers, the most actionable patent buckets are:

• Combination composition claims (budesonide + formoterol in a defined ratio and/or with controlled characteristics)
• Formulation claims (excipients, particle engineering, spray-dry/co-spray properties where applicable)
• Manufacturing process claims (mixing, granulation/coating, particle size control)
• Method-of-use claims (asthma/COPD dosing regimens, exacerbation-reducing regimens)
• Continuations/divisionals that extend active prosecution and sometimes maintenance of exclusivity coverage

Why claims breadth drives business outcomes

For inhalers:

• Broad composition claims can delay generic acceptance.
• More specific process or particle-property claims can allow “design-around” strategies if the generic pathway can meet bioequivalence requirements while avoiding literal claim scope.

(No patent numbers are included because the prompt does not provide the Orange Book listing, NDA/ANDA identifiers, or a specific patent estate dataset to cite accurately.)

---

What is the Orange Book status of SYMBICORT, and what does it imply for launch calendars?

Quick answer: Orange Book status is the gating mechanism for FDA-recognized exclusivity and listed patents, but launch calendars require the exact NDA number, listed patent numbers, and listed expiration dates.

What to extract from the Orange Book for competitive modeling

For SYMBICORT, the high-value fields to model are:

• Listed patent numbers and their expiration dates
• Which patents are tied to:
  • composition/formulation
  • method-of-use
  • device/delivery system
• Any patent that is the basis for:
  • Paragraph IV filings
  • approved generic/authorized generic entries

(No Orange Book table is included because the prompt does not include the Orange Book listing or NDA identifier needed for an accurate status summary.)

---

How does SYMBICORT compare with competing ICS/LABA drugs on commercial dynamics?

Quick answer: The commercial contest in ICS/LABA is driven by payer preference, copay strategy, and COPD step-up patterns more than by marginal clinical differences.

Comparison dimensions that move share

Inhaler class comparisons that consistently predict share changes include:

• Net price after rebates vs competitor
• PBM preferred tier placement
• Step therapy frequency and prior authorization rules
• Device preference and patient restart costs
• Co-prescribing with rescue inhalers and adherence patterns

Typical competitor “attack vector”

Competitors generally pressure SYMBICORT through:

• Aggressive contracting to win preferred status
• Lower list price strategies with comparable net economics
• Push for formulary switching in asthma and COPD maintenance cohorts

---

What patent litigation affects SYMBICORT generic entry risk?

Quick answer: Litigation timing controls whether a lower-cost entrant launches immediately at the first allowed date or is delayed by injunction risk, design-around, or settlement.

What to track in SYMBICORT litigation for business decisions

For market entry planning, the key litigation signals are:

• Whether a Paragraph IV challenge was brought and whether it was successful
• Whether a settlement included:
  • launch timing commitments
  • covenants not to sue
  • licensing terms
• Court outcomes that clarify claim scope and design-around viability

(No litigation docket dates or case names are included because none are provided in the prompt.)

---

Did SYMBICORT face Paragraph IV challenges, and what were the commercial impacts?

Quick answer: Paragraph IV activity is relevant only with identified filings, affected patents, and settlement or court outcomes.

Why this matters for financial trajectory

If a Paragraph IV filer wins:

• The market sees earlier generic competition
• Net price pressure accelerates
• Brand volume declines can accelerate due to PBM formulary changes

If the filer loses:

• Brand can keep market economics stable longer
• Any generic entry may be delayed or limited to non-covered channels

(No specific Paragraph IV results are provided because they require docket and FDA/Orange Book linkage data not included in the prompt.)

---

What are SYMBICORT’s formulation and device factors that influence competitive substitution?

Quick answer: Inhalation performance, dose uniformity, and patient usability drive real-world persistence, which affects switching rates even when substitutes are on formulary.

Device and patient-handling constraints

Key practical switching determinants:

• Inhaler ergonomics and perceived ease of use
• Patient technique training and pharmacy support
• Device preference reinforced by prior authorizations

Clinical interchange and labeling consistency

Switching accelerates when:

• The competitor product has closely aligned label dosing and administration instructions
• Prescribers accept interchange without additional monitoring requirements

---

Key commercial timeline: how SYMBICORT revenue tends to evolve through product lifecycle

Quick answer: Older inhaler brands typically show a pattern of steady baseline demand with phased erosion driven by contracting and class competition.

Modeling timeline structure for revenue forecasting (framework)

Use a lifecycle schedule built on:

• Formulary tier changes by PBMs
• Generic entry or authorized generic introduction events (if any)
• COPD triple-therapy adoption rates
• Cohort persistence and adherence trends

Typical year-to-year patterns in brand ICS/LABA

• Early lifecycle: growth driven by uptake, guideline adoption, and payer coverage expansions
• Mid lifecycle: plateau with net price compression
• Late lifecycle: gradual share loss as preferred alternatives expand and patients switch at refill

(No exact dates are included because the prompt does not include SYMBICORT annual sales disclosures or competitor entry dates.)

---

Key Takeaways

• SYMBICORT’s market trajectory is governed by ICS/LABA class competition, payer contracting, and COPD care pathway migration, producing gradual erosion rather than a sudden collapse typical of single exclusivity cliffs.
• Realized financial performance depends on gross-to-net management and formulary positioning, not only on clinical demand.
• Patent and Orange Book status affect launch timing and injunction risk, but the prompt does not provide the Orange Book/NDA patent identifiers needed to map exact expiration and entry calendars.
• Device usability and patient persistence can slow switching, but PBM step therapy and preferred-tier contracting can still drive volume shifts.

---

FAQs

1. How do PBM step edits and prior authorization rules affect SYMBICORT persistence rates?
2. What net price compression is typical for mature ICS/LABA brands when competing generics gain preferred status?
3. How does COPD triple-therapy adoption change the addressable market for ICS/LABA combinations like SYMBICORT?
4. What business indicators best predict an inhaler brand’s near-term revenue downside (TRx trend vs net price vs rebate mix)?
5. How do inhaler device switching frictions influence substitution after payer formulary updates?

---

References

1. (No sources were provided in the prompt to cite. No external documents are included.)

DrugChatter Q&A for SYMBICORT

Symbicort us sales growth?
Symbicort spray patentschutz?
Symbicort loss of exclusivity?
When will symbicort go generic?
Symbicort compound patent expire?